Sermorelin vs. semaglutide: weight-loss evidence and practical differences

Approved product and ingredient are different questions

The current Wegovy prescribing information includes both injectable and oral tablet formulations. The route, eligible population, indication, and instructions need to be checked for the specific product. It is no longer accurate to describe all Wegovy treatment as an injection.

This does not make an oral sermorelin product equivalent to an approved oral semaglutide product. Different molecules and formulations have different absorption characteristics and supporting evidence. Our oral bioavailability guide explains why “dissolves in the mouth” cannot establish the amount of sermorelin that reaches the bloodstream.

Compounded medications are not FDA-approved. A historical approval involving sermorelin also does not approve every current compounded formulation. The regulatory-status guide separates the ingredient’s history from the status of the finished medicine offered today.

What the STEP 1 study tells us

The STEP 1 trial enrolled 1,961 adults with overweight or obesity, without diabetes, and studied a once-weekly subcutaneous semaglutide regimen over 68 weeks. It compared treatment with placebo alongside lifestyle intervention and measured body-weight outcomes.

That is direct evidence about the studied injectable regimen and population. It is not a trial of sermorelin, and it does not establish that every oral, injectable, or compounded product has identical outcomes. Different routes and formulations require their own supporting evidence and instructions.

Our sermorelin weight-loss guide explains the more limited basis for general weight-loss claims about sermorelin. A change in growth-hormone signaling should not be presented as the same evidence as a large trial measuring weight change.

Body composition needs more than a headline

An exploratory STEP 1 body-composition conference abstract describes DXA findings in 140 participants. It reports changes in fat and lean tissue during treatment. This smaller analysis is a different type of evidence from the main trial’s weight outcome and does not directly establish changes in muscle strength.

It also did not test adding sermorelin. Claims that sermorelin will preserve muscle during semaglutide treatment therefore need separate evidence. The combination guide explains the questions to ask if a program makes that proposal.

For an adult worried about weakness, the clinical discussion should include physical function, food intake, activity, and other possible causes. A scale result or hormone test cannot answer all of those questions.

Different safety questions require different follow-up

Wegovy’s label includes gastrointestinal risks, delayed gastric emptying, and other precautions. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. The boxed warning concerns thyroid C-cell tumors seen in rodents; it does not establish that every thyroid condition carries the same risk.

Sermorelin raises a different set of questions about hormone-related symptoms, the treatment indication, and the quality and evidence for the actual compounded preparation. A product marketed as supporting “natural” hormone release should still have a clear monitoring and reassessment plan.

Read our side-effect guide and give the clinician the complete medication list. These summaries help identify questions; they do not replace the product label or a clinical review of personal risk.

Make the comparison about a real treatment plan

Ask what diagnosis or goal the prescription addresses, which evidence applies, what follow-up is included, and what would prompt a change in treatment. For cost comparisons, include consultations, laboratory work, medication, supplies, shipping, and renewal fees over the same period.

If the main goal is weight management, discuss options with direct evidence for that condition. If a hormone disorder is suspected, clarify the assessment rather than assuming a weight-loss medicine and sermorelin are alternatives for the same diagnosis. The tirzepatide comparison provides another example of why medication names and marketing categories are not enough to choose treatment.